본문바로가기
Q
U
I
C
K

Science & Technology

SK bioscience provides various vaccine platforms based on the company's R&D and manufacturing capabilities.

Pipeline

As infectious diseases keep spreading across the globe, threatening the human race.
expanding the vaccine market is critical more than ever.

SK bioscience will continue to invest in vaccine R&D which will be the driving force of life science business
to secure the newest technology and expand a product portfolio.

Domestic Vaccine Market

(Year of 2017~2028, Unit: billion $)

  • 0
  • 20
  • 40
  • 60
  • 80
  • 100
  • 120

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Source: BIS Research, Global Vaccine Market - Analysis and Forecast: 2018 to 2028, 2018.11, Recreated by Biotech Policy Research Center(BPRC)

The premium vaccine market is growing as the aging population is rapidly increasing.

The growing vaccine industry is resulting in better profitability, introduction of new R&D and manufacturing technologies, and new funding opportunities.

In recent years, the development of therapeutic vaccines which can treat currently existing diseases is also on the rise.

Vaccines are the most effective, efficient, and convenient to prevent and treat infectious diseases.
Immunization through vaccination has become the most important public health policy in the world to prevent the outbreak of transboundary epidemics.
Vaccine Pipeline
Approved iconApproved
PIPELINE - SKYVAX, Phase Ⅰ/ Ⅱ, Phase Ⅲ, BLA, Commercial, WHO PQ
Basic Research / Preclinical Phase I Clinical Trial Phase II Clinical Trial Phase III Clinical Trial Commercialization
Cell Culture-based
Influenza Quadrivalent
chk
chk
chk
chk
COVID-19 Vaccine
CEPIBILL MELINDA GATES FOUNDATION
chkAchieved BLA /
of SKYCovione (KMFDS)
Combination Vaccine
chk
Universal Coronavirus
Vaccine (Sarbecovirus)
CEPIprotein design
chk
Nasal Spray*
IAVIBILL MELINDA GATES FOUNDATION
chk
COVID-19 mRNA Vaccine
chk
Next-Gen
Pneumococcal Vaccine
SANOFL RASTEUR
chkU.S.
RSV Vaccine
chk
Cancer Immunotherapies,
Obesity Vaccines, etc
chk
Typhoid Conjugate Vaccine
INTERNATIONAL VACCINE INSTITUTEBILL MELINDA GATES FOUNDATION
chkEarned
a biologics license
for export
Cervical Cancer Vaccine
(4-/10-valent)
chk Phase I/II
Clinical Trial
Rotavirus Vaccine1)
chk
iNTS2) Vaccine*
(Non-Typhoidal Salmonella)
chk
Hepatitis A, Recombinant
Herpes Zoster Vaccines, etc.
chk
Etc.
Development and global M&A in progress

1) Non-Replicating Rotavirus Vaccine
2) Invasive Non-Typhoidal Salmonella
* Collaboration Project